Positives

• Patients reported reductions in waist circumference disproportionate to weight loss, consistent with preferential visceral fat mobilization PeptideEvidence.
  
  
• Unlike full GH, AOD-9604 did not impair glucose tolerance or raise IGF-1 in glucose-clamp studies, useful for LC-related metabolic dysfunction PubMed.
  
  

Negatives

• In its largest Phase IIb obesity trial of 900+ participants, AOD-9604 failed to beat placebo, prompting the developer to halt the program in 2007 PeptideEvidence.
  
  
• Patients typically waited 12+ weeks for visible results, with no guarantee of response PeptideEvidence.
  
  

Hurdles & Side Effects

• AOD-9604 is not an approved drug; it carries only US food-ingredient GRAS status and Australian cartilage-repair recognition PeptideEvidence.
  
  
• Patients must source from compounding pharmacies or research suppliers, with no insurance coverage PeptideEvidence.